Claryx raises $3.5M to spot hospital outbreaks before they spread
What's the deal? New York City-based ClaryxDealroom has a profile for this one. Try Dealroom →, founded by Ontario brothers Kurt and Dirk Hackenberger, has raised $3.5 million (US$3.59M) in pre-seed funding for its CloneLink platform, which it says can detect problematic pathogens before they trigger hospital outbreaks. New York VC firm OutlanderDealroom has a profile for this one. Try Dealroom → led the round.
Backers included Company VenturesDealroom has a profile for this one. Try Dealroom →, Boost VC, NeonDealroom has a profile for this one. Try Dealroom →, Mana VenturesDealroom has a profile for this one. Try Dealroom →, 640 OxfordDealroom has a profile for this one. Try Dealroom →, and Precursor VenturesDealroom has a profile for this one. Try Dealroom →.
What's the endgame? Claryx sequences the "metagenome" of an entire hospital — sampling wastewater, air from different wards, and sink swabs — to map where pathogens hide. When a patient contracts a transmissible infection, it compares the genetic sequence to that map and flags exactly where the bacteria is lurking.
"Instead of noticing when infections are popping up in your hospital after the fact, it's actually identifying them upstream," Kurt Hackenberger said.
Why now? Infections acquired in healthcare settings, such as those caused by Clostridioides difficile (C. diff), affect roughly one in 38 US hospital patients on any given day, according to the US Center for Disease Control and Prevention. They cost the US healthcare system billions of dollars a year. Kurt and Dirk's grandmother nearly died after contracting C. diff and sepsis during a routine check-up — the "genesis," Kurt said, behind building a proactive solution.
The tech: The platform builds on Dirk's doctoral work at McMaster University under antimicrobial resistance researcher Dr. Gerard Wright. He developed a proprietary method to cut the cost of metagenomic sequencing, letting Claryx run continuous tests without cost as a bottleneck.
Why the US first? Despite its Canadian roots, Claryx is piloting with hospitals in New York state because selling into a privately funded system is simpler. "There's a far higher burden if you're vending into the Canadian government," Kurt said, noting the nearly 100 hospitals near its New York City headquarters offer a dense pool of potential customers. It is already working with two hospitals.
The signal: Claryx reflects a wider pattern of Canadian life sciences founders building at home but launching stateside, where procurement is faster. Medtech leaders have called for simpler pathways across Canada's provincial systems as more startups treat the US as their first customer.
Read more: BetaKit
Image credit: Generated with Gemini
